Compound Muji Granules enhances cisplatin efficacy against alpha-fetoprotein-producing gastric cancer by suppressing epidermal growth factor receptor signaling
Hui Li, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Li Wang, Sen Zuo, Fourth Clinical Medical College of Xinjiang Medical University, Urumqi 830099, Xinjiang Uygur Autonomous Region, China
Wen-Ting He, Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Co-corresponding authors: Wen-Ting He and Tong Zhang.
Author contributions: Li H contributed to conceptualization, methodology, investigation, writing original draft; Wang L contributed to software, validation, formal analysis, writing review and editing; Zuo S contributed to software, data curation, visualization, writing review and editing; He WT contributed to writing review and editing, supervision, project administration, funding acquisition; Zhang T contributed to resources, writing review and editing, supervision, project administration; He WT and Zhang T contributed equally to this work as co-corresponding authors; all authors have read and approved the final manuscript and agree to be accountable for all aspects of the work.
AI contribution statement: The authors declare that no AI tools were used in the preparation of this manuscript or in the response to reviewers’ comments.
Supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region, No. 2022D01C561.
Institutional animal care and use committee statement: No human participants, identifiable human data, primary human tissues, or animals were involved in this study. No animals were involved; therefore, animal ethics approval were not required.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Tong Zhang, MD, Doctor, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China.
ashtray45671@outlook.com
Received: February 24, 2026
Revised: April 22, 2026
Accepted: May 27, 2026
Published online: June 24, 2026
Processing time: 120 Days and 4.4 Hours
